KALA BIO (KALA) Competitors $5.70 -0.15 (-2.56%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$5.75 +0.05 (+0.88%) As of 07/14/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. DMAC, IMRX, LFVN, LXEO, GLSI, LYEL, MOLN, THTX, CGEN, and IKTShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include DiaMedica Therapeutics (DMAC), Immuneering (IMRX), Lifevantage (LFVN), Lexeo Therapeutics (LXEO), Greenwich LifeSciences (GLSI), Lyell Immunopharma (LYEL), Molecular Partners (MOLN), Theratechnologies (THTX), Compugen (CGEN), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors DiaMedica Therapeutics Immuneering Lifevantage Lexeo Therapeutics Greenwich LifeSciences Lyell Immunopharma Molecular Partners Theratechnologies Compugen Inhibikase Therapeutics DiaMedica Therapeutics (NASDAQ:DMAC) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Do analysts rate DMAC or KALA? DiaMedica Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 99.50%. KALA BIO has a consensus price target of $13.00, indicating a potential upside of 128.07%. Given KALA BIO's higher probable upside, analysts clearly believe KALA BIO is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer DMAC or KALA? In the previous week, KALA BIO had 10 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 11 mentions for KALA BIO and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.89 beat KALA BIO's score of 0.18 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Overall Sentiment DiaMedica Therapeutics Very Positive KALA BIO Neutral Do institutionals and insiders believe in DMAC or KALA? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 7.3% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 8.3% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, DMAC or KALA? DiaMedica Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, meaning that its stock price is 288% less volatile than the S&P 500. Is DMAC or KALA more profitable? DiaMedica Therapeutics' return on equity of -61.35% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -61.35% -55.53% KALA BIO N/A -369.29%-64.99% Which has better valuation and earnings, DMAC or KALA? DiaMedica Therapeutics has higher earnings, but lower revenue than KALA BIO. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-6.27KALA BIO$3.89M9.45-$38.51M-$8.24-0.69 SummaryKALA BIO beats DiaMedica Therapeutics on 7 of the 13 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.77M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E Ratio-0.6921.1628.6919.45Price / Sales9.45184.72373.1779.78Price / CashN/A41.0524.7227.47Price / Book2.827.758.255.58Net Income-$38.51M-$55.05M$3.19B$252.81M7 Day Performance10.47%9.69%3.53%2.11%1 Month Performance32.56%13.80%9.56%11.87%1 Year Performance-25.10%3.55%30.54%16.61% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.9525 of 5 stars$5.70-2.6%$13.00+128.1%-23.8%$36.77M$3.89M-0.6930News CoverageAnalyst UpgradeGap UpDMACDiaMedica Therapeutics1.1992 of 5 stars$3.61-1.7%$8.00+121.7%+15.6%$155.01MN/A-5.6520IMRXImmuneering3.427 of 5 stars$4.22-2.7%$13.25+214.4%+236.3%$151.72MN/A-2.1560LFVNLifevantage4.3326 of 5 stars$12.03-2.8%$30.50+153.6%+102.8%$151.57M$200.16M17.45260LXEOLexeo Therapeutics2.3583 of 5 stars$4.47-2.6%$16.60+271.4%-74.8%$149.87M$650K-1.3758Gap UpGLSIGreenwich LifeSciences2.1756 of 5 stars$10.96-2.3%$39.00+255.8%-30.8%$146.54MN/A-8.703LYELLyell Immunopharma3.5142 of 5 stars$9.86+0.9%$15.00+52.2%-71.7%$145.92M$65K-0.39270Positive NewsMOLNMolecular Partners3.0963 of 5 stars$3.61+1.5%$12.00+232.9%-42.6%$145.55M$2.23M-1.88180THTXTheratechnologiesN/A$3.16+0.2%N/A+119.5%$145.07M$85.87M-16.61140Earnings ReportCGENCompugen1.6271 of 5 stars$1.63-3.8%$4.00+146.2%-9.7%$145.02M$27.86M-10.1670IKTInhibikase Therapeutics1.2273 of 5 stars$1.94-3.0%$6.50+235.1%+33.3%$143.85MN/A-0.726 Related Companies and Tools Related Companies DiaMedica Therapeutics Competitors Immuneering Competitors Lifevantage Competitors Lexeo Therapeutics Competitors Greenwich LifeSciences Competitors Lyell Immunopharma Competitors Molecular Partners Competitors Theratechnologies Competitors Compugen Competitors Inhibikase Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALA Stock Alerts